190 related articles for article (PubMed ID: 35750560)
1. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
Kwon DH; Paciorek A; Zhang L; Borno HT; Bucknor M; Small EJ; Aggarwal RR
Urol Oncol; 2022 Aug; 40(8):379.e17-379.e24. PubMed ID: 35750560
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
[TBL] [Abstract][Full Text] [Related]
3. Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.
Pilon D; Behl AS; Ellis LA; Emond B; Lefebvre P; Dawson NA
J Manag Care Spec Pharm; 2017 Feb; 23(2):225-235. PubMed ID: 28125362
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide.
Baser O; Samayoa G; Dwivedi A; AlSaleh S; Cigdem B; Kizilkaya E
Acta Oncol; 2024 Apr; 63():137-146. PubMed ID: 38591349
[TBL] [Abstract][Full Text] [Related]
5. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
Trieu J; Chang M; Rojas V; Varada N; Cao Y; Anderson M; Vogelzang NJ
Clin Genitourin Cancer; 2022 Oct; 20(5):399-403. PubMed ID: 35680530
[TBL] [Abstract][Full Text] [Related]
6. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
[TBL] [Abstract][Full Text] [Related]
10. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.
McGregor B; Zhang L; Gray KP; Shaw G; Evan C; Francini E; Sweeney C
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):341-348. PubMed ID: 32884090
[TBL] [Abstract][Full Text] [Related]
11. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
[TBL] [Abstract][Full Text] [Related]
12. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
13. Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T; Tokushige S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Ohno T; Nakamori K; Maenosono R; Nishimura K; Yamazaki S; Uchimoto T; Yanagisawa T; Mori K; Urabe F; Tsuzuki S; Iwatani K; Yamamoto S; Takahara K; Inamoto T; Kimura T; Ohno Y; Shiroki R; Azuma H
Cancer Med; 2023 Oct; 12(19):19414-19422. PubMed ID: 37706578
[TBL] [Abstract][Full Text] [Related]
14. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.
Zhang W; Wu TY; Chen Q; Shi XL; Xiao GA; Zhao L; Xu CL; Zhou T; Sun YH
Asian J Androl; 2017; 19(2):196-202. PubMed ID: 27212123
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
[TBL] [Abstract][Full Text] [Related]
18. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Chen HK; Su PJ; Wang YL; Chang KC; Su YL; Chang PH; Kuan FC; Hsieh CH; Kuo YC; Sheng TW; Chang CF; Yu SM; Huang WK; Lin YC; Tsan DL; Yu KJ; Lin PH; Chen HY; Chang YH; Pang ST; Chuang CK; Lai EC
Int J Cancer; 2023 Mar; 152(6):1191-1201. PubMed ID: 36346116
[TBL] [Abstract][Full Text] [Related]
19. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
